The earnings call highlighted significant revenue growth and strategic progress with product launches and FDA clearances. However, ongoing operating losses and administrative challenges in Europe were noted as areas of concern. Overall, the positive developments outweigh the negatives.

Company Guidance -

Q3 2025

During the second quarter of 2025, Stereotaxis reiterated its revenue guidance for the full year, projecting double-digit growth. The company achieved a total revenue of $8.8 million, marking a 95% increase compared to the previous year's second quarter and an 18% sequential rise. System revenue reached $3 million, while recurring revenue was $5.8 million. Stereotaxis also highlighted the progress of its GenesisX system, which received CE Mark approval in Europe and is pending FDA clearance in the U.S. The introduction of new catheters, such as MAGiC Sweep, is expected to significantly boost revenue per procedure and expand the user base. Operating expenses for the quarter were $8.6 million, with adjusted operating expenses at $6 million. The company ended the quarter with $7 million in cash and announced a subsequent $12.5 million financing, bolstering its cash position to $18.8 million.

Significant Revenue Growth

Revenue for the second quarter of 2025 totaled $8.8 million, a growth of 95% from $4.5 million in the prior year second quarter and a growth of 18% sequentially compared to $7.5 million in the first quarter of 2025.

Successful GenesisX and MAGiC Launches

Revenue recognition on the first GenesisX system and initial MAGiC sales in Europe contributed significantly to the quarter's financial performance.

FDA Clearance and Regulatory Progress

FDA clearance of the MAGiC Sweep high-density mapping catheter marked a major milestone, along with ongoing regulatory steps for GenesisX and other products.

Strategic Financing

Stereotaxis announced a registered direct financing for the sale of $12.5 million of its shares, with a first closing of $8.5 million completed in July, strengthening the balance sheet.

Strong Gross Margins on Recurring Revenue

Recurring revenue gross margin was 68% for the quarter.

Stereotaxis (STXS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

STXS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.06 / -	-0.08	―	―	―
Aug 07, 2025	2025 (Q2)	-0.07 / -0.05	-0.07	28.57% (+0.02)	―
May 12, 2025	2025 (Q1)	-0.07 / -0.07	-0.06	-16.67% (-0.01)	―
Mar 03, 2025	2024 (Q4)	-0.07 / -0.09	-0.07	-28.57% (-0.02)	―
Nov 11, 2024	2024 (Q3)	-0.05 / -0.08	-0.07	-14.29% (>-0.01)	―
Aug 12, 2024	2024 (Q2)	-0.05 / -0.07	-0.07	0.00% (0.00)	―
May 13, 2024	2024 (Q1)	-0.06 / -0.06	-0.07	14.29% (+0.01)
Mar 04, 2024	2023 (Q4)	-0.07 / -0.07	-0.06	-16.67% (-0.01)	―
Nov 09, 2023	2023 (Q3)	-0.06 / -0.07	-0.07	0.00% (0.00)	―
Aug 10, 2023	2023 (Q2)	-0.07 / -0.07	-0.07	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

STXS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$2.19	$2.50	+14.16%
May 12, 2025	$2.07	$2.11	+1.93%
Mar 03, 2025	$2.06	$1.94	-5.83%
Nov 11, 2024	$1.85	$2.26	+22.16%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Stereotaxis (STXS) report earnings?

Stereotaxis (STXS) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Stereotaxis (STXS) earnings time?

Stereotaxis (STXS) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is STXS EPS forecast?

STXS EPS forecast for the fiscal quarter 2025 (Q3) is -0.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing